Management of Anemia in Cancer Patients
- 4 April 2011
- journal article
- review article
- Published by Informa UK Limited in Future Oncology
- Vol. 7 (4), 507-517
- https://doi.org/10.2217/fon.11.24
Abstract
Cancer-related anemia adversely affects quality of life and is associated with reduced overall survival. The correction of anemia in cancer patients has the potential to improve treatment efficacy and increase survival. A large number of studies demonstrate that treatment of anemia in cancer patients using erythropoiesis-stimulating agents (ESAs) significantly increases hemoglobin levels, decreases transfusion requirements and improves quality of life, predominantly by reducing fatigue. Some data on the use of ESAs in cancer patients indicate an increased risk of thromboembolic events and a possibly increased risk of mortality. However, there is ample evidence that when ESAs are used within current guidelines, they are valuable and safe drugs for the treatment of anemia in patients receiving radiotherapy and/or chemotherapy. There are increasing data from prospective, randomized trials demonstrating better responses to ESAs with the concurrent use of iron. Blood transfusions are also helpful in the management of anemia in cancer patients, especially when there is a need for immediate increases in hemoglobin levels. In this article, we discuss recent aspects relating to treatment modalities for anemia in cancer patients.Keywords
This publication has 63 references indexed in Scilit:
- Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Patients With Chemotherapy-Associated AnemiaJournal of Clinical Oncology, 2011
- Epoetin Alfa Improves Anemia and Anemia-Related, Patient-Reported Outcomes in Patients with Breast Cancer Receiving Myelotoxic Chemotherapy: Results of a European, Multicenter, Randomized, Controlled TrialThe Oncologist, 2010
- Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) studyEuropean Journal Of Cancer, 2009
- Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysisCMAJ : Canadian Medical Association Journal, 2009
- Blood Transfusion Promotes Cancer Progression: A Critical Role for Aged ErythrocytesAnesthesiology, 2008
- Blood Transfusions, Thrombosis, and Mortality in Hospitalized Patients With CancerArchives of Internal Medicine, 2008
- Effect of treatment with epoetin-β on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patientsBritish Journal of Cancer, 2008
- Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancerGynecologic Oncology, 2008
- Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated AnemiaJAMA, 2008
- EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancerEuropean Journal Of Cancer, 2004